Quality of life for people with early-stage breast cancer who participated in the OlympiA clinical trial
https://www.facingourrisk.org/XRAY/olaparib-quality-of-life
Full article: https://www.youtube.com/watch?v=kCS_QqWS7x0
The OlympiA study showed that the PARP inhibitor olaparib (Lynparza) is effective when used as maintenance therapy for people with an inherited BRCA1 or BRCA2 mutation who have early-stage breast cancer. Patient-reported outcomes from OlympiA suggest that olaparib was well tolerated and did not reduce quality of life or delay recovery from chemotherapy. (posted 2/22/22) Update: Based on OlympiA results, the FDA approved olaparib as adjuvant treatment for people with an inherited BRCA mutation who were diagnosed with early-stage HER2-negative breast cancer at high risk for recurrence. (03/11/2022).
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- Are PARP inhibitors recommended for my type of breast cancer?
- What side effects are associated with PARP inhibitors?
- Will using a PARP inhibitor worsen my treatment-related side effects?
- How can I reduce side effects related to treatments or PARP inhibitors?
- How long will I have to use PARP inhibitors?
- Will my insurance pay for PARP inhibitor treatment?
- I have a mutation in a gene other than BRCA1 or BRCA2; will PARP inhibitors help treat my cancer?
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.